

Final height and body mass index in English and Italian adult survivors of childhood acute lymphoblastic leukemia (ALL) treated without cranial radiotherapy.

P. Bruzzi¹, A. Albanese², S. Nussey³, B. Predieri⁴, L. lughetti⁴, A. Leiper⁵

¹Azienda Ospedaliera-Universitaria Policlinico, Paediatric Department, Modena, Italy; ²Royal Marsden Hospital, Paediatric Oncology Unit, Sutton, UK; ³St Georges Hospital, Endocrine Unit, London, UK; ⁴University of Modena & Reggio Emilia, Department of Medical Sciences of Mothers, Children and Adults, Paediatric Unit, Modena, Italy; ⁵Great Ormond Street Hospital for Children, Haematology Unit, London, UK

INTRODUCTION

Adult survivors of childhood ALL treated with protocols including cranial radiotherapy (CRT) demonstrated a persistent increased body mass index (BMI) and a reduced final height (FH). To date, long-term data on growth in survivors exposed only to chemotherapy (CT) are only available from small numbers.




STUDY DESIGN, PATIENTS AND METHODS

AIM OF THE STUDY

• To investigate the effect of CT alone on BMI and FH in an international and wide

cohort of childhood ALL survivors.

Figure 1. Study Population



• Inclusion criteria:


- Successful completion of CT (Italy: AIEOP ALL 87, 88, 91, 95 and 2000 protocols, UK: UKALL XI protocol)

- Being in first remission
- Achievement of FH
- Exclusion criteria:
- Relapse
- Exposure to CRT and/or
- bone marrow transplant
- Presence of other diseases or therapies that could influence growth
- Lack of data

• Height- and BMI-SDS were calculated for each value using age- and sex-matched population standards (www.who.org). • Data were summarized using standard statistics (STATISTICA[™] software, StatSoft Inc., Tulsa, OK, USA).

• Local Ethical Committees approved the protocol study.






Height-SDS

(eT) and FH

Legend: Dex: Dexamethasone exposure ≥250 mg/m²

2a. Changes in Height-SDS over time



р

FH-SDS

Albeit in an older cohort (than UK), the Italian data show:


• a reduction of Height-SDS in both sexes


 an increase in BMI-SDS during CT in both genders, but only girls maintain the increase at FH.

SDS Height end treat SDS Height final 3a. Changes in BMI-SDS over time 1.0 * * 0,8

Legend: A: Asian; AA: Afro-Caribbean; Dex: Dexamethasone exposure 100 mg/m²

2b. Changes in Height-SDS over time





CONCLUSIONS

1. Italian AIEOP protocols reduce Height-SDS in both sexes. They are associated with an increase in BMI-SDS at the end of CT. Only Italian girls show an increased final BMI-SDS.

2.UKALL XI reduces Height-SDS in girls but not in boys. It has no effect on BMI-SDS in either sex at FH.

3. Previous data on UKALL 97 (no CRT) showed an adverse effect on BMI-SDS of girls but not boys at FH (Harper RLC et al. BJH 2013; 163:510-513). UKALL 97 differs from UKALL

XI in randomizing dexamethasone at induction (with mercaptopurine/thioguanine). As the Italian protocols all contain more dexamethasone than UKALL XI, exposure to high

doses of this glucocorticoid might contribute to changes in BMI of female survivors of childhood ALL. However, the effect of high-dose methotrexate cannot be excluded.